

Acinetobacter baumannii, Strain MRSN 14193

Catalog No. NR-52191

This reagent is the tangible property of the U.S. Government.

Product Description:

Acinetobacter baumannii (*A. baumannii*), strain MRSN 14193 was isolated in 2012 from a human wound sample in Central America as part of a global surveillance program. *A. baumannii*, strain MRSN 14193 was deposited as sensitive to colistin, intermediately resistant to tobramycin, and resistant to amikacin, ampicillin/sulbactam, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, imipenem, levofloxacin, meropenem, tetracycline and trimethoprim/sulfamethoxazole. NR-52191 lot 70039042 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70039042

Manufacturing Date: 10SEP2020

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis Cellular morphology Colony morphology Growth at 44°C ± 2°C ¹ 1 day in an aerobic atmosphere on Tryptic Soy agar Motility Remel™ Motility Test Medium w/TTC Indicator for 1 day at 37°C in an aerobic atmosphere VITEK® MS (MALDI-TOF)	Gram-negative rods Report results Growth Report results <i>A. baumannii</i>	Gram-negative rods Circular, convex, entire, smooth and cream (Figure 1) Growth Non-motile <i>A. baumannii</i> (99.9%)
Antibiotic Susceptibility Profile^{2,3} Amikacin Ampicillin/sulbactam Cefepime Ceftriaxone Ceftazidime Ciprofloxacin Colistin Gentamicin Imipenem Levofloxacin Meropenem Trimethoprim/sulfamethoxazole Tobramycin Tetracycline	Resistant Resistant Resistant Resistant Resistant Resistant Sensitive Resistant Resistant Resistant Resistant Resistant Resistant Resistant Intermediate Resistant	Resistant (> 256 µg/mL) Resistant (48 µg/mL) Resistant (> 256 µg/mL) Resistant (≥ 64 µg/mL) Resistant (≥ 64 µg/mL) Resistant (≥ 4 µg/mL) Sensitive (≤ 2 µg/mL) Resistant (≥ 16 µg/mL) Resistant (> 8 µg/mL) Resistant (≥ 32 µg/mL) Resistant (> 8 µg/mL) Resistant (4 µg/mL) Intermediate (8 µg/mL) Resistant (> 256 µg/mL)
Genotypic Analysis Sequencing of 16S ribosomal RNA gene (~ 1470 base pairs)	≥ 99% sequence identity to <i>A. baumannii</i> , strain MRSN 14193 (GenBank: VHGZ01000068.1)	100% sequence identity to <i>A. baumannii</i> , strain MRSN 14193 (GenBank: VHGZ01000068.1)


TEST	SPECIFICATIONS	RESULTS
Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability	Growth	Growth

¹Growth at 44°C differentiates *A. baumannii* from *A. calcoaceticus* and *A. pittii*, which do not grow at 44°C.

²Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

³Antibiotic susceptibility was tested using a combination of VITEK[®]2 GN82, Sensititre GNX2F AST and E-test strips.

Figure 1: Colony Morphology



/Heather Couch/
Heather Couch

14 JAN 2022

Program Manager or designee, ATCC Federal Solutions

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

